SGLT2 抑制剂和糖尿病病:针对多种和相互关联的信号通路进行脏保护
1K.M.P THERAPIS Paphos Medical Center, Internal Medicine and Diabetes Clinic, 14 Vasileos Georgiou B Street, Office 201, 8010, Paphos, Cyprus.
Current molecular pharmacology
|October 31, 2023
概括
-葡萄糖共运输体2 (SGLT2) 抑制剂为糖尿病病患者提供了显著的益处. 这些药物通过超出血糖控制的多种途径改善脏健康,降低死亡风险.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病病影响20-40%的糖尿病患者,增加死亡率.
- 多种病理生理机制驱动糖尿病病的进展.
- 对于多目标疗法有着至关重要的需求.
研究的目的:
- 研究糖尿病患者SGLT2抑制剂对的益处背后的机制.
- 探索SGLT2抑制剂在控制慢性病进展中的作用.
- 突出SGLT2抑制剂的多目标治疗潜力.
主要方法:
- 审查体外研究,探索性研究和随机对照试验的子分析.
- 对生物标志物调查的分析.
- 专注于受SGLT2抑制剂影响的细胞和分子通路.
主要成果:
- SGLT2 抑制剂表现出有益的功能,独立于抗高血糖效应.
- 关键的机制包括降低体内压力,TGF恢复和RAAS调节.
- 在缺氧,新陈代谢,线粒体功能,炎症,氧化应激和纤维化中观察到的改善.
结论:
- SGLT2 抑制剂代表了对2型糖尿病和糖尿病病的改变实践的治疗方法.
- 他们的多目标行动为改善慢性病演变提供了一个有希望的策略.
- 了解这些机制对于优化SGLT2抑制剂在糖尿病管理中的使用至关重要.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
192
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
192
Oral Hypoglycemic Agents: Biguanides and Glitazones
212
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
212
Glucagon-like Receptor Agonists
334
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
334
Antihypertensive Drugs: Direct Renin Inhibitors
650
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
650
Oral Hypoglycemic Agents: Glinides
160
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
160
Chronic Kidney Disease III: Interprofessional Care
21
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
21


